Half-year report · Q2
3151.TEDINET S100UNVO
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥297.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥587.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥294.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥2.9bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥2.9bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.5bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.5bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥2.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥317.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥317.3bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥321.7bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥207.9bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥211.3bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥109.6bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥105.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥102.8bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥19.7bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥34.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥16.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥31.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥9.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥48.75 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.03 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.78 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥88m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥6.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥6.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥285.0bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥279.5bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥9.7bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥9.7bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥96m |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥144m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥300.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥294.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥303.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥297.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥3.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥108m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | ¥39m |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥282.5bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥277.2bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.4bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥9.4bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥114m |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥183m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥297.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥292.2bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5.3bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥300.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥294.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 543
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 5647000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 294913000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2165000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 297079000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 297079000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 5454000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E22440-000PharmacyBusinessReportableSegmentMember | 6000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 5460000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1341000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 6802000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -6802000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 284995000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E22440-000PharmacyBusinessReportableSegmentMember | 9731000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 5647000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 300374000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3507000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 303881000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -6802000000 | JPY |
| Net sales | CurrentYTDDuration | 297079000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E22440-000MedicalProductsWholesaleReportableSegmentsMember | 2724000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E22440-000PharmacyBusinessReportableSegmentMember | 96000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember | 144000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 2964000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -88000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2876000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -0 | JPY |
| Operating income | CurrentYTDDuration | 2876000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-08 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第16期中(自 2024年４月１日 至 2024年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社バイタルケーエスケー・ホールディングス | |
| Company name in english cover page | FilingDateInstant | VITAL KSK HOLDINGS, INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 村 井 泰 介 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都世田谷区弦巻一丁目１番12号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)(03)5787－8550(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経理財務担当 喜 多 勇 夫 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪府大阪市中央区本町橋１-20 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)(06)6941－1207(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経理財務担当 喜 多 勇 夫 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E22440 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 31510 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社バイタルケーエスケー・ホールディングス | |
| Filer name in english | FilingDateInstant | VITAL KSK HOLDINGS,INC. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |